The Promise of CGRP Antibodies to Change Practice in Migraine Treatment
PROGRAM DESCRIPTION In this activity, the faculty will cover today’s clinical environment and the challenges associated with the effective preventive treatment of chronic migraines. Dr. Lipton, Dr. Charles, and Dr. ...
PROGRAM DESCRIPTION
In this activity, the faculty will cover today’s clinical environment and the challenges associated with the effective preventive treatment of chronic migraines. Dr. Lipton, Dr. Charles, and Dr. Dodick will also highlight the challenges currently encountered by patients and clinicians when implementing current preventive treatment for migraine and share the promising new therapies on the horizon. This e-Monograph will include insights and understandings about how these new therapies work, the unique features of the calcitonin gene-related peptide (CGRP) monoclonal antibodies, how these four new agents have performed in clinical trials and, most importantly, how they may impact practice.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:Identify the unmet needs resulting from ineffective prevention of migraineDescribe the role of CGRP in the pathophysiology of migraineCompare and contrast emerging treatments currently in clinical trials which show promise to improve patient outcomes in the preventative treatment of episodic and chronic migraine
Read more about this
Write the first review
Join now
to leave a review or read peer reviews!
Resource tags
Show all tags
